What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs

Abstract

BackgroundConsiderable emphasis is presently being placed on usage of generic medicines by governments focussed on the potential economic benefits associated with their use. Concurrently, there is increasing discussion in the lay media of perceived doubts regarding the quality and equivalence of generic medicines. The objective of this paper is to report the outcomes of a systematic search for peer-reviewed, published studies that focus on physician, pharmacist and patient/consumer perspectives of generic medicines.MethodsLiterature published between January 2003 and November 2014, which is indexed in PubMed and Scopus, on the topic of opinions of physicians, pharmacists and patients with respect to generic medicines was searched, and articles within the scope of this review were appraised. Search keywords used included perception, opinion, attitude and view, along with keywords specific to each cohort.ResultsFollowing review of titles and abstracts to identify publications relevant to the scope, 16 papers on physician opinions, 11 papers on pharmacist opinions and 31 papers on patient/consumer opinions were included in this review. Quantitative studies (n = 37) were the most common approach adopted by researchers, generally in the form of self-administered questionnaires/surveys. Qualitative methodologies (n = 15) were also reported, albeit in fewer cases. In all three cohorts, opinions of generic medicines have improved but some mistrust remains, most particularly in the patient group where there appears to be a strongly held belief that less expensive equals lower quality. Acceptance of generics appears to be higher in consumers with higher levels of education while patients from lower socioeconomic demographic groups, hence generally having lower levels of education, tend to have greater mistrust of generics.ConclusionsA key factor in improving confidence in generic products is the provision of information and education, particularly in the areas of equivalency, regulation and dispelling myths about generic medicines (such as the belief that they are counterfeits). Further, as patient trust in their physician often overrules their personal mistrust of generic medicines, enhancing the opinions of physicians regarding generics may have particular importance in strategies to promote usage and acceptance of generic medicines in the future.

Knowledge, Attitude and Practice of Resident Doctors for use of Generic Medicines at a Tertiary care Hospital

“…A systematic review and critical appraisal had suggested information and education regarding bioequivalence, regulations and quality of generic medicines can improve prescription of these drugs. 19 Respondents expressed variable opinions regarding regulation of compulsory prescription of generic drugs in a tertiary care teaching hospital. While compulsory prescription can greatly reduce healthcare expenditure, prescribers may have apprehensions regarding quality and efficacy of these drugs and hence, some (18%) chose not to agree.…”

Development and testing of a web module to IMPROVE generic prescribing of oral contraceptives among primary care physicians

“…Focus groups conducted at the American College of Physicians (ACP) Internal Medicine Meeting showed that providers have low knowledge of FDA bioequivalence standards and concerns of decreased efficacy of generic options, commenting that “generics are not going to be efficacious.” Participants identified potential solutions to generic prescribing, including increased access to information and educational material about generic medication. Additionally, Dunne et al showed “a key factor in improving the confidence of…(physicians) is the provision of information and education, particularly in the areas of equivalency, regulation and in dispelling myths about generic medicines.”…”

Can biosimilars help achieve the goals of US health care reform?

“…A US survey of specialty physicians prescribing biologics conducted between November 2015 and January 2016 found a general lack of understanding and pressing need for education about biosimilars, particularly about the FDA approval process; the definition, safety, and efficacy of biologics versus biosimilars; and regulatory guidance for indication extrapolation, interchangeability, and pharmacy-level substitution 45. The generic market serves as an example of how practice changes as clinicians become more familiar with these alternate products (in particular, the uptake of generics such as warfarin and thyroid medication) 55–57. Biosimilar uptake ultimately depends upon education – increased understanding about biosimilar production, regulation, and mechanism of action as well as experience in clinical practice.…”